Associations of Cannabis and Tobacco Use with Suicide Attempt, Suicide Death, and Overdose Death Among Veterans Prescribed Opioid Analgesics.
Associations of Cannabis and Tobacco Use with Suicide Attempt, Suicide Death, and Overdose Death Among Veterans Prescribed Opioid Analgesics.
Cannabis use among Veterans prescribed opioids was associated with reduced risk of suicide attempts and overdose deaths compared to non-cannabis users in this large longitudinal cohort study.
This study provides large-scale longitudinal evidence that cannabis use may be associated with protective effects against suicide-related outcomes in Veterans prescribed opioids. The finding challenges assumptions about cannabis as uniformly harmful in vulnerable populations and suggests potential therapeutic mechanisms worth investigating.
Veterans face disproportionately high suicide rates, and opioid-prescribed populations carry additional overdose risk. Understanding whether cannabis use patterns correlate with protective or harmful outcomes in this high-risk population directly informs clinical risk assessment and counseling approaches.
| Study Type | Longitudinal Cohort Study |
| Population | 923,291 Veterans prescribed opioid analgesics, median follow-up 6.7-6.8 years |
| Intervention | Cannabis use (5.4% of cohort) and tobacco use (39.4% of cohort) assessed at baseline |
| Comparator | Non-cannabis users and non-tobacco users within the same cohort |
| Primary Outcome | Suicide attempts, suicide deaths, and overdose deaths over 2-year follow-up period |
| Key Finding | Cannabis use associated with reduced risk of suicide attempts and overdose deaths |
| Journal | American Journal of Preventive Medicine |
| Year | 2024 |
Among Veterans prescribed opioids, cannabis use was associated with lower risks of suicide attempts and overdose deaths compared to non-use. This observational finding warrants careful interpretation but suggests cannabis use should not be automatically viewed as additive risk in suicide prevention protocols for this population.
The study cannot establish causation between cannabis use and reduced suicide/overdose risk, nor does it provide information about cannabis dosing, products, or consumption patterns. The mechanism underlying any protective effect remains unexplored and speculative.
Observational design cannot control for unmeasured confounders that might explain both cannabis use patterns and suicide risk differences. The study lacks data on cannabis use motivation, frequency, or therapeutic intent, which could substantially influence interpretation of these associations.
Cannabis use among opioid-prescribed Veterans correlated with reduced suicide and overdose risk in this large cohort, but causation cannot be inferred. Clinicians should avoid stigmatizing cannabis use in suicide risk assessments while recognizing that correlation does not establish therapeutic benefit.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
Does cannabis use increase suicide risk in Veterans prescribed opioids?
Contrary to common assumptions, this study found that cannabis use was associated with reduced risk of suicide attempts and overdose deaths among Veterans prescribed opioids. The protective association persisted even after adjusting for established risk factors including substance use disorders and mental health conditions.
How does tobacco use affect suicide and overdose risk in this population?
The study found that 39.4% of Veterans in the cohort used tobacco at baseline, representing a much higher prevalence than cannabis use (5.4%). While specific tobacco-related outcomes aren’t detailed in the summary, tobacco use was assessed as a potential risk indicator alongside other established factors.
Should clinicians be concerned about cannabis use in Veterans on opioid therapy?
Based on this evidence, cannabis use may not warrant the same level of concern as other substance use regarding suicide and overdose risk. However, clinicians should still monitor all substance use patterns and consider individual patient factors when assessing overall risk profiles.
How long were these Veterans followed to assess outcomes?
The study followed 923,291 Veterans for a median of 6.7-6.8 years, with data collection spanning from 2014-2019 and outcomes tracked through 2021. This extended follow-up period strengthens the reliability of the observed associations between substance use patterns and clinical outcomes.
Can these findings be applied to non-Veteran populations on opioid therapy?
While this study provides valuable insights, the findings are specific to the Veteran population, which may have unique characteristics including higher rates of PTSD, combat exposure, and specific healthcare access patterns. Further research is needed to determine if similar protective associations exist in civilian populations prescribed opioids.
